The FDA approves RedHill Biopharma’s (NASDAQ:RDHL) Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Commercial launch will commence in Q1 2020.
The company will host an Analyst & Investor Day on November 22 to discuss the launch.
Shares up 17% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.